ILLUMINATE

Clinical Trial

NCT03913143 Active, Not recruiting

ILLUMINATE

A double-masked, randomized, controlled, multiple-dose study to evaluate the efficacy, safety, tolerability and systemic exposure of QR-110 in Subjects with Leber’s Congenital Amaurosis (LCA) due to c.2991+1655A>G mutation (p.Cys998X) in the CEP290 gene (Illuminate).

Phase 2/3

Interventional

Disease

Disease type

Paediatric clinical trials

Orphan drug recognition

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

04/04/2019

Closing date

04/12/2021

Inclusion criteria :

Exclusion criteria :

Funding

industry

Members involved

Others investigators

Pr Bart LEROY

Representative

Belgium

Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Working Group Leader

Pr Elfride DE BAERE

Substitute

Belgium

Genetic Diagnostics (TWG6), Retinal Rare Eye Diseases (WG1)

Working Group Leader

Pr Carel HOYNG

Representative

Netherlands

Genetic Diagnostics (TWG6), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)

PD Dr Markus Preising

Representative

Germany

Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Dr Katarina Stingl

Representative

Germany

Low Vision Daily Life and Patients Groups (TWG5), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Working Group Leader

Pr Isabelle Audo

Representative

France

Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Neuro-Ophthalmology Rare Diseases (WG2), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Pr Hélène Dollfus

Representative

France

Anterior Segment Rare Eye Diseases (WG4), CPMS & Digital Medecine (TWG10), Epag, ERN-EYE Coordinating committee, Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Neuro-Ophthalmology Rare Diseases (WG2), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Working Group Leader

ERN EYE member investigating site

See full page

Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Accessibility

ILLUMINATE

In this page

Clinical Trial

Disease

Inclusion / Exclusion

Funding

Members involved

Others investigators

Pr Bart LEROY

Pr Elfride DE BAERE

Pr Carel HOYNG

PD Dr Markus Preising

Dr Katarina Stingl

Pr Isabelle Audo

Pr Hélène Dollfus

ERN EYE member investigating site

HCP : Principal investigators

Ghent University Hospital, Ghent, Belgium

Adress

Contact

Radboud university medical center, Nijmegen, Netherlands

Adress

Contact

Universitätsklinikum Gießen und Marburg GmbH, Gießen, Germany

Adress

Contact

Centre for Ophthalmology, University Eye Hospital, Tübingen, Germany

Adress

Contact

CARGO, Hôpitaux Universitaires de Strasbourg, France

Adress

Contact

RÉFÉRET National Hospital of Ophthalmology of Quinze-Vingts, Paris, France

Adress

Contact